In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
Author(s)BioPharm International Editors
Pall ForteBio introduces a solution for quantifying residual host cell proteins in CHO cells.
Advertisement
Pall ForteBio announced on Oct. 20, 2014 the launch of a new solution for quantifying contaminating residual host cell proteins (HCPs) in Chinese hamster ovary (CHO) cells, the most commonly used mammalian hosts for industrial production of recombinant protein therapies. The new tool, the Dip and Read Anti-CHO Host Cell Protein Detection Kit, helps with the detection and reduction of residual HCPs that are left behind by CHO cells. The residual products can negatively affect the efficacy and safety of a final drug product. The kit accelerates the drug delivery timeline by providing better assay precision and complements Pall’s ForteBio Octet Platform.
“The commonly used ELISA HCP analytical method can require up to overnight analysis and must be monitored. Our new Dip and Read high-precision assay kit, in combination with the Octet HTX system, is hands-free, and only takes around an hour to analyze 96 samples with detection sensitivity as low as 0.5 ng/mL,” says Yves Baratelli, president of Pall Life Sciences, in a press release. “This translates into a dramatic advance in the user’s process, and a drastic reduction in their time and capital investment from development through to production.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5